Xinyan Zhang

Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients

K. Chayama, T. Pilot‐Matias, M. Burroughs, 2017, Advances in Therapy.

Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir

K. Chayama, T. Pilot‐Matias, M. Burroughs, 2015, Antimicrobial Agents and Chemotherapy.

Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial

D. Arnold, D. Reich, M. Valis, 2021, The Lancet Neurology.